HOPE PHARMA SOLUTIONS LTD
Company number 09734961 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
1. Industry Classification
Hope Pharma Solutions Ltd is registered under SIC code 86900 — Other human health activities. This is a residual classification covering a broad range of non-hospital, non-GP health services, including allied health professionals, community health practitioners, health screening services and certain private or specialist care activities. It is distinct from retail pharmacy (SIC 47730), GP practices (SIC 86210) and hospital activities (SIC 86101).
The company’s previous names — Hope Online Limited and Hope Online Pharmacy Ltd — indicate an origin in online pharmacy and digital healthcare. The 2019 rebrand to “Pharma Solutions” suggests a strategic shift away from direct dispensing and toward a services, consultancy or support-based model within the pharmaceutical/health ecosystem.
The company is a micro-entity under Companies House filing categories, meaning it is exempt from full statutory disclosure, including the profit and loss account. It is also audit-exempt, with no independent auditor’s report.
2. Relative Performance
The accounts show a business that is financially substantial for its filing category:
- Total assets: £581,340 (down from £619,441 in 2024)
- Net assets: £461,379 (down from £478,550)
- Current assets: £480,720, against current liabilities of just £49,978
- Net current assets: £430,742
- Current ratio: approximately 9.6 — a very strong liquidity position
The balance sheet reflects clear improvement over the company’s earlier history. In 2016–2019, shareholder funds were consistently negative, reaching -£48,918 in 2020. The business then turned sharply positive, with net assets peaking at £555,526 in 2022. Since then, net assets have declined modestly each year — from £555,526 (2022) to £513,040 (2023), £478,550 (2024) and £461,379 (2025). This is not a crisis, but it suggests a plateau or gradual contraction.
Fixed assets fell from £164,621 to £100,620, likely reflecting depreciation of equipment, vehicles or leasehold improvements. Meanwhile, current assets increased from £454,820 to £480,720, suggesting cash or short-term receivables remain healthy.
The average employee count fell from 3 to 1 between 2024 and 2025. For a micro business, that is a meaningful reduction in operational capacity and may indicate outsourcing, automation, or a strategic move toward a leaner consultancy-style model.
Against sector norms, this is a well-capitalised niche player. Many micro-entity businesses in the broader human health sector operate with minimal fixed assets and thin reserves. Hope Pharma Solutions carries a substantial asset base and very low short-term debt. That said, because micro-entity accounts do not disclose turnover, gross profit or operating costs, a full profitability comparison against industry benchmarks is not possible.
3. Sector Trends Impact
The UK “other human health activities” sector is being shaped by several structural trends:
- NHS waiting lists and elective care backlogs continue to push demand toward independent and private health providers, which benefits service-oriented health businesses.
- Pharmacy First, introduced in England in January 2024, has shifted more minor-ailment treatment into pharmacy settings, creating opportunities and regulatory pressure for companies positioned between pharmacy and primary care.
- Digital health and e-pharmacy consolidation means small online pharmacy models face intense competition from large digital platforms and established high-street chains expanding online.
- The regulatory environment — CQC, MHRA, GPhC and data protection requirements — is heavy for patient-facing health businesses. A “pharma solutions” model may be less exposed to dispensing margins and more exposed to NHS commissioning budgets, private client spending and pharmaceutical industry outsourcing.
- Drug supply volatility, reimbursement pressures and rising input costs continue to squeeze traditional pharmacy economics, which may explain the company’s earlier pivot away from a pure online pharmacy brand.
The company’s shift to “solutions” suggests it is attempting to occupy a niche between clinical delivery and commercial/operational pharmaceutical services. That space is sensitive to public-sector spending cycles but generally benefits from the structural growth of health outsourcing and specialisation.
4. Competitive Positioning
Hope Pharma Solutions is best described as a niche player. It is not a market leader in scale, and its headcount indicates a very lean operating structure. However, its balance sheet strength gives it resilience that many comparable micro health businesses lack.
Strengths:
- Strong solvency and liquidity, with negligible net debt and a current ratio well above sector norms
- Established track record since 2015, with a successful turnaround from negative reserves
- Experienced board representation and a clear controlling owner with a direct stake in the company’s success
- Clean Companies House compliance — accounts and confirmation statements are up to date
Weaknesses:
- Heavy concentration of voting control: name shown to subscribers holds over 75% of the company’s shares and voting rights
- Declining net assets in three consecutive years, driven partly by falling fixed assets
- A reduction to an average of one employee may limit the company’s ability to scale or deliver complex client engagements
- No turnover disclosure under micro-entity rules, making competitive benchmarking against larger health service providers difficult
The competitive field includes large online pharmacies, specialist healthcare consultancies and multidisciplinary private clinics. Against these, Hope Pharma Solutions’ advantages are its small footprint, clean balance sheet and sector adaptability — but its growth capacity is constrained by its ownership structure and limited human resources.